266 related articles for article (PubMed ID: 17785576)
1. Targeting lymphotoxin beta receptor with tumor-specific T lymphocytes for tumor regression.
Yang D; Ud Din N; Browning DD; Abrams SI; Liu K
Clin Cancer Res; 2007 Sep; 13(17):5202-10. PubMed ID: 17785576
[TBL] [Abstract][Full Text] [Related]
2. Tumor-specific CTL kill murine renal cancer cells using both perforin and Fas ligand-mediated lysis in vitro, but cause tumor regression in vivo in the absence of perforin.
Seki N; Brooks AD; Carter CR; Back TC; Parsoneault EM; Smyth MJ; Wiltrout RH; Sayers TJ
J Immunol; 2002 Apr; 168(7):3484-92. PubMed ID: 11907109
[TBL] [Abstract][Full Text] [Related]
3. The Fas/Fas ligand pathway is important for optimal tumor regression in a mouse model of CTL adoptive immunotherapy of experimental CMS4 lung metastases.
Caldwell SA; Ryan MH; McDuffie E; Abrams SI
J Immunol; 2003 Sep; 171(5):2402-12. PubMed ID: 12928387
[TBL] [Abstract][Full Text] [Related]
4. Lymphotoxin-β receptor activation by lymphotoxin-α(1)β(2) and LIGHT promotes tumor growth in an NFκB-dependent manner.
Daller B; Müsch W; Röhrl J; Tumanov AV; Nedospasov SA; Männel DN; Schneider-Brachert W; Hehlgans T
Int J Cancer; 2011 Mar; 128(6):1363-70. PubMed ID: 20473944
[TBL] [Abstract][Full Text] [Related]
5. In vivo rejection of tumor cells dependent on CD8 cells that kill independently of perforin and FasL.
Lee SH; Bar-Haim E; Machlenkin A; Goldberger O; Volovitz I; Vadai E; Tzehoval E; Eisenbach L
Cancer Gene Ther; 2004 Mar; 11(3):237-48. PubMed ID: 14739939
[TBL] [Abstract][Full Text] [Related]
6. Perforin, Fas/Fas ligand, and TNF-alpha pathways as specific and bystander killing mechanisms of hepatitis C virus-specific human CTL.
Ando K; Hiroishi K; Kaneko T; Moriyama T; Muto Y; Kayagaki N; Yagita H; Okumura K; Imawari M
J Immunol; 1997 Jun; 158(11):5283-91. PubMed ID: 9164947
[TBL] [Abstract][Full Text] [Related]
7. Concanamycin A, a powerful tool for characterization and estimation of contribution of perforin- and Fas-based lytic pathways in cell-mediated cytotoxicity.
Kataoka T; Shinohara N; Takayama H; Takaku K; Kondo S; Yonehara S; Nagai K
J Immunol; 1996 May; 156(10):3678-86. PubMed ID: 8621902
[TBL] [Abstract][Full Text] [Related]
8. Perforin-independent CD8(+) T-cell-mediated cytotoxicity of alveolar epithelial cells is preferentially mediated by tumor necrosis factor-alpha: relative insensitivity to Fas ligand.
Liu AN; Mohammed AZ; Rice WR; Fiedeldey DT; Liebermann JS; Whitsett JA; Braciale TJ; Enelow RI
Am J Respir Cell Mol Biol; 1999 May; 20(5):849-58. PubMed ID: 10226053
[TBL] [Abstract][Full Text] [Related]
9. Tumor regression after adoptive transfer of effector T cells is independent of perforin or Fas ligand (APO-1L/CD95L).
Winter H; Hu HM; Urba WJ; Fox BA
J Immunol; 1999 Oct; 163(8):4462-72. PubMed ID: 10510388
[TBL] [Abstract][Full Text] [Related]
10. Perforin and Fas induced by IFNgamma and TNFalpha mediate beta cell death by OT-I CTL.
McKenzie MD; Dudek NL; Mariana L; Chong MM; Trapani JA; Kay TW; Thomas HE
Int Immunol; 2006 Jun; 18(6):837-46. PubMed ID: 16574667
[TBL] [Abstract][Full Text] [Related]
11. Immune selection and emergence of aggressive tumor variants as negative consequences of Fas-mediated cytotoxicity and altered IFN-gamma-regulated gene expression.
Liu K; Caldwell SA; Abrams SI
Cancer Res; 2005 May; 65(10):4376-88. PubMed ID: 15899830
[TBL] [Abstract][Full Text] [Related]
12. Comparing the relative role of perforin/granzyme versus Fas/Fas ligand cytotoxic pathways in CD8+ T cell-mediated insulin-dependent diabetes mellitus.
Kreuwel HT; Morgan DJ; Krahl T; Ko A; Sarvetnick N; Sherman LA
J Immunol; 1999 Oct; 163(8):4335-41. PubMed ID: 10510373
[TBL] [Abstract][Full Text] [Related]
13. Anti-idiotype antibody induced cellular immunity in mice transgenic for human carcinoembryonic antigen.
Saha A; Chatterjee SK; Foon KA; Bhattacharya-Chatterjee M
Immunology; 2006 Aug; 118(4):483-96. PubMed ID: 16895556
[TBL] [Abstract][Full Text] [Related]
14. Cytolytic T-cell cytotoxicity is mediated through perforin and Fas lytic pathways.
Lowin B; Hahne M; Mattmann C; Tschopp J
Nature; 1994 Aug; 370(6491):650-2. PubMed ID: 7520535
[TBL] [Abstract][Full Text] [Related]
15. Identification of a population of CD4+ CTL that utilizes a perforin- rather than a Fas ligand-dependent cytotoxic mechanism.
Williams NS; Engelhard VH
J Immunol; 1996 Jan; 156(1):153-9. PubMed ID: 8598456
[TBL] [Abstract][Full Text] [Related]
16. Two types of anti-TL (thymus leukemia) CTL clones with distinct target specificities: differences in cytotoxic mechanisms and accessory molecule requirements.
Tsujimura K; Takahashi T; Iwase S; Matsudaira Y; Kaneko Y; Yagita H; Obata Y
J Immunol; 1998 Jun; 160(11):5253-61. PubMed ID: 9605121
[TBL] [Abstract][Full Text] [Related]
17. Peptide modification or blocking of CD8, resulting in weak TCR signaling, can activate CTL for Fas- but not perforin-dependent cytotoxicity or cytokine production.
Kessler B; Hudrisier D; Schroeter M; Tschopp J; Cerottini JC; Luescher IF
J Immunol; 1998 Dec; 161(12):6939-46. PubMed ID: 9862728
[TBL] [Abstract][Full Text] [Related]
18. Essential roles of perforin in antigen-specific cytotoxicity mediated by human CD4+ T lymphocytes: analysis using the combination of hereditary perforin-deficient effector cells and Fas-deficient target cells.
Yanai F; Ishii E; Kojima K; Hasegawa A; Azuma T; Hirose S; Suga N; Mitsudome A; Zaitsu M; Ishida Y; Shirakata Y; Sayama K; Hashimoto K; Yasukawa M
J Immunol; 2003 Feb; 170(4):2205-13. PubMed ID: 12574394
[TBL] [Abstract][Full Text] [Related]
19. Fas-independent cytotoxicity mediated by human CD4+ CTL directed against herpes simplex virus-infected cells.
Yasukawa M; Ohminami H; Yakushijin Y; Arai J; Hasegawa A; Ishida Y; Fujita S
J Immunol; 1999 May; 162(10):6100-6. PubMed ID: 10229852
[TBL] [Abstract][Full Text] [Related]
20. In vivo analysis of adenovirus-specific cytotoxic T lymphocyte response in mice deficient in CD28, fas ligand, and perforin.
Chen J; Hsu HC; Zajac AJ; Wu Q; Yang P; Xu X; McPherson SA; Li J; Curiel DT; Mountz JD
Hum Gene Ther; 2006 Jun; 17(6):669-82. PubMed ID: 16776575
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
